These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 16760297)

  • 1. Cetuximab for treatment of metastatic colorectal cancer.
    Cerea G; Ricotta R; Schiavetto I; Maugeri MR; Sartore-Bianchi A; Moroni M; Artale S; Siena S
    Ann Oncol; 2006 Jun; 17 Suppl 7():vii66-7. PubMed ID: 16760297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cetuximab in the treatment of metastatic colorectal cancer.
    Moosmann N; Heinemann V
    Expert Opin Biol Ther; 2007 Feb; 7(2):243-56. PubMed ID: 17250462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-epidermal growth factor receptor antibodies in the treatment of metastatic colorectal cancer.
    Lee D
    Clin Colorectal Cancer; 2004 Sep; 4(3):159-62. PubMed ID: 15377399
    [No Abstract]   [Full Text] [Related]  

  • 4. Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies.
    Zhang W; Gordon M; Lenz HJ
    Ann Med; 2006; 38(8):545-51. PubMed ID: 17438669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cetuximab: appraisal of a novel drug against colorectal cancer.
    Hildebrandt B; le Coutre P; Nicolaou A; Köble K; Riess H; Dörken B
    Recent Results Cancer Res; 2007; 176():135-43. PubMed ID: 17607921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer.
    Lee JJ; Chu E
    Clin Colorectal Cancer; 2007 Oct; 6 Suppl 2():S42-6. PubMed ID: 18021486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
    Jean GW; Shah SR
    Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integration of novel agents in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
    Lenz HJ; Van Cutsem E; Khambata-Ford S; Mayer RJ; Gold P; Stella P; Mirtsching B; Cohn AL; Pippas AW; Azarnia N; Tsuchihashi Z; Mauro DJ; Rowinsky EK
    J Clin Oncol; 2006 Oct; 24(30):4914-21. PubMed ID: 17050875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
    Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancer.
    Wen F; Li Q
    World J Gastroenterol; 2016 Jun; 22(23):5332-41. PubMed ID: 27340349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
    Cunningham D; Humblet Y; Siena S; Khayat D; Bleiberg H; Santoro A; Bets D; Mueser M; Harstrick A; Verslype C; Chau I; Van Cutsem E
    N Engl J Med; 2004 Jul; 351(4):337-45. PubMed ID: 15269313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter Phase II study of cetuximab plus irinotecan in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines.
    Tahara M; Shirao K; Boku N; Yamaguchi K; Komatsu Y; Inaba Y; Arai T; Mizunuma N; Satoh T; Takiuchi H; Nishina T; Sakata Y
    Jpn J Clin Oncol; 2008 Nov; 38(11):762-9. PubMed ID: 18836202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cetuximab.
    Goldberg RM
    Nat Rev Drug Discov; 2005 May; Suppl():S10-1. PubMed ID: 15962524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective on the inhibition of epidermal growth factor receptor as a therapeutic strategy for patients with relapsed metastatic colorectal cancer: impact on treatment of today's patients.
    Jackson C; Cunningham D
    Clin Colorectal Cancer; 2007 Dec; 7 Suppl 1():S8-15. PubMed ID: 18361806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cetuximab in colon cancer.
    Giuliani F; Colucci G
    Int J Biol Markers; 2007; 22(1 Suppl 4):S62-70. PubMed ID: 17520583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cetuximab in previously treated colorectal cancer.
    Starling N; Cunningham D
    Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S28-33. PubMed ID: 15871763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
    Wong SF
    Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current and emerging therapies for metastatic colorectal cancer: applying research findings to clinical practice.
    Hecht JR
    Am J Health Syst Pharm; 2008 Jun; 65(11 Suppl 4):S15-21; quiz S22-4. PubMed ID: 18499885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.